Lupus anticoagulants (LA) are heterogeneous autoantibodies of the IgG and IgM type directly directed against a variety of anionic phospholipids such as cardiolipin, phosphatidylserine or phosphatidylinositol or against proteins having the capacity to bind to phospholipids such as β2-glycoprotein I (β2-GPI) .
The presence of LA is primarily detected using sensitive in vitro tests using phospholipids, such as APTT (Activated Partial Thromboplastin Time) or dRVVT.
They have the in vitro capacity to prolong phospholipid-dependent clotting times but are most often associated with thrombotic complications in vivo (venous or arterial thrombosis, thrombocytopenia and fetal losses) and do not predispose to a risk of bleeding. DRVVT is routinely used in screening for LA. It is considered specific and robust.
Each batch is supplied with a certificate of analysis showing the following results:
- TCA (sensitive lupus)
- TCA (mixed 1 : 1 Pool)
- TCA on silica (SCT)
- Kaolin Clotting Time
- dRVVT report
- LA hexagonal phase
- PNP (platelet neutralization)
- IgG / IgA / IgM :
Anti-cardiolipin
Anti-β-2-glycoprotéin 1
Anti-phosphatidylsérin
- Ready to use after thawing, saves time.
- Hex LA is compatible with many automated coagulation analyzers, providing a quick and easy detection method in a panel of tests.
- Protocols available on request.
- 2 vials x 1.5 mL LA Start
- 2 vials x 1.5 mL LA Correct
- 2 vials x 3 mL LA APTT for HEXLA
- 3 vials x 3 mL of LA APTT for HEXLA-7